Corbus Pharmaceuticals Holdings Bilan de santé

Santé financière contrôle des critères 5/6

Corbus Pharmaceuticals Holdings possède un total de capitaux propres de $125.5M et une dette totale de $10.8M, ce qui porte son ratio d'endettement à 8.6%. Son actif total et son passif total sont $152.0M et de $26.4M.

Informations clés

8.6%

Ratio d'endettement

US$10.82m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$147.03m
Fonds propres	US$125.54m
Total du passif	US$26.44m
Total des actifs	US$151.98m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 3371 ( $148.3M ) dépassent ses passifs à court terme ( $24.0M ).

Passif à long terme: Les actifs à court terme de 3371 ( $148.3M ) dépassent ses passifs à long terme ( $2.5M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 3371 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 3371 est passé de 0.2% à 8.6% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 3371 dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: 3371 dispose d'une marge de trésorerie suffisante pour 2.5 ans si le flux de trésorerie disponible continue de croître à un taux historique de 3.4 % chaque année.

Corbus Pharmaceuticals Holdings Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Nasdaq Gants Corbus Pharmaceuticals Holdings an Extension Until May 8, 2024 to Regain Compliance

Corbus Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market, Under Listing Rule 5550(b)(1)

Corbus Pharmaceuticals Holdings Gets a 180-Day Extension to January 2, 2023, to Regain Compliance with the Minimum Bid Price Requirement

Corbus Pharmaceuticals Holdings Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Recent updates

Corbus Pharmaceuticals Holdings, Inc. Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Corbus Pharmaceuticals Holdings, Inc. Announces Board and Committee Changes

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 16, 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Negative shareholders equity

Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering.

Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701 (SYS6002)

Nasdaq Gants Corbus Pharmaceuticals Holdings an Extension Until May 8, 2024 to Regain Compliance

Corbus Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market, Under Listing Rule 5550(b)(1)

Corbus Pharmaceuticals Holdings, Inc. Presents Results of Two Pre-Clinical Studies on its Anti-VETA>8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. Appoints Anne Altmeyer to Board of Directors

First half 2022 earnings released: US$0.18 loss per share (vs US$0.28 loss in 1H 2021)

Corbus Pharmaceuticals Holdings Gets a 180-Day Extension to January 2, 2023, to Regain Compliance with the Minimum Bid Price Requirement

Corbus Pharmaceuticals Holdings, Inc. Enters into a Binding Term Sheet with Venn Therapeutics, LLC, to Resolve the Claims by Venn Against the Corbus Pharmaceuticals Holdings, Inc

Corbus Pharmaceuticals Holdings, Inc. Announces That New Preclinical Data for CRB-601 Are Being Presented in an Oral Presentation At the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference in New York

First quarter 2022 earnings released: US$0.075 loss per share (vs US$0.14 loss in 1Q 2021)

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 18, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Corbus Pharmaceuticals Holdings Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Third quarter 2021 earnings released: US$0.017 loss per share (vs US$0.43 loss in 3Q 2020)

Head of Research & Chief Medical Officer Barbara White has left the company

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.52 loss in 2Q 2020)

Corbus Pharmaceuticals Holdings, Inc.(NasdaqGM:CRBP) dropped from Russell 3000E Growth Index

Corbus Pharmaceuticals Announces Topline Results from Determine Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Corbus Pharmaceuticals Holdings, Inc. Announces Licensing Deals for Two New Monoclonal Antibodies, CRB-601 and CRB-602 to Further Expand Pipeline into Cancer and Fibrotic Diseases

Forecast to breakeven in 2024

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.43 loss in 1Q 2020)

Full year 2020 earnings released: US$1.42 loss per share (vs US$1.12 loss in FY 2019)

Corbus Pharmaceuticals Holdings, Inc. Provides Clinical Program Updates

Corbus Pharmaceuticals Holdings, Inc. to Report Q4, 2020 Results on Mar 15, 2021

New 90-day high: €1.87

New 90-day high: €1.25

Corbus Pharmaceuticals Holdings, Inc. Announces the Resignation of Robert Discordia as Chief Operating Officer

Corbus Pharmaceuticals Holdings, Inc. Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis

Corbus Pharmaceuticals Holdings, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Robert Discordia Will No Longer Serve as Chief Operating Officer of Corbus Pharmaceuticals Holdings, Inc

New 90-day low: €1.01

Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint

New 90-day high - €7.81

Corbus Pharmaceuticals Holdings, Inc. to Report Q2, 2020 Results on Aug 06, 2020

New 90-day low - €5.38

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines